Alcidion Group (ALC) Stock Overview
Engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ALC from our risk checks.
ALC Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alcidion Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.11 |
| 52 Week High | AU$0.14 |
| 52 Week Low | AU$0.082 |
| Beta | 1.1 |
| 1 Month Change | 4.76% |
| 3 Month Change | 10.00% |
| 1 Year Change | 17.02% |
| 3 Year Change | 18.28% |
| 5 Year Change | -75.56% |
| Change since IPO | 69.23% |
Recent News & Updates
Narrative Update • Jun 04
ALC: FY26 Revenue Visibility And Margin Improvement Will Support Higher Multiple
Alcidion Group's analyst fair value target has been revised to A$0.1475 from A$0.1425, with analysts citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. Analyst Commentary Analysts have updated their view on Alcidion Group with a modest increase in the fair value target to A$0.1475.Narrative Update • May 12
ALC: FY26 Revenue Visibility And Cash Generation Progress Will Support Higher Multiple
Analysts have maintained Alcidion Group's fair value estimate at A$0.14, while making modest adjustments to discount rate, revenue growth, and profit margin assumptions. These changes reflect refreshed sector research and updated modeling rather than a directional shift in the stock's thesis.Narrative Update • Apr 24
ALC: FY26 Revenue Visibility And M&A Optionality Will Support Higher Multiple
Analysts have left Alcidion Group's fair value estimate unchanged at A$0.14 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, reflecting refreshed sector research and updated medical technology peer comparisons. Analyst Commentary Recent sector research in global medical technology has focused heavily on large listed peers rather than Alcidion Group directly, but the themes still matter if you are thinking about valuation and execution risk for a smaller health tech name.Recent updates
Narrative Update • Jun 04
ALC: FY26 Revenue Visibility And Margin Improvement Will Support Higher Multiple
Alcidion Group's analyst fair value target has been revised to A$0.1475 from A$0.1425, with analysts citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. Analyst Commentary Analysts have updated their view on Alcidion Group with a modest increase in the fair value target to A$0.1475.Narrative Update • May 12
ALC: FY26 Revenue Visibility And Cash Generation Progress Will Support Higher Multiple
Analysts have maintained Alcidion Group's fair value estimate at A$0.14, while making modest adjustments to discount rate, revenue growth, and profit margin assumptions. These changes reflect refreshed sector research and updated modeling rather than a directional shift in the stock's thesis.Narrative Update • Apr 24
ALC: FY26 Revenue Visibility And M&A Optionality Will Support Higher Multiple
Analysts have left Alcidion Group's fair value estimate unchanged at A$0.14 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, reflecting refreshed sector research and updated medical technology peer comparisons. Analyst Commentary Recent sector research in global medical technology has focused heavily on large listed peers rather than Alcidion Group directly, but the themes still matter if you are thinking about valuation and execution risk for a smaller health tech name.Narrative Update • Apr 09
ALC: FY26 Revenue Delivery And Cash Deployment Will Support Higher Multiple
Analysts have maintained the Alcidion Group price target at A$0.14, with only small adjustments to the discount rate and long term assumptions. This reflects updated sector research that incorporates recent medtech coverage but does not materially alter the valuation view.Narrative Update • Mar 25
ALC: Higher Future Multiple Will Depend On Delivering FY26 Revenue And M&A Execution
Alcidion Group's analyst price target is unchanged at A$0.14, with analysts making only minor adjustments to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions as they refresh models in line with broader medtech coverage updates. Analyst Commentary Analysts keeping Alcidion Group's A$0.14 price target unchanged are broadly aligning the stock with recent adjustments seen across the wider medical technology coverage, where peers have seen both upgrades and downgrades as models are refreshed after Q4 reporting and sector updates.Narrative Update • Mar 10
ALC: Higher Future Multiple Will Rely On Executing FY26 Revenue Pipeline
Analysts trimmed their fair value estimate for Alcidion Group to A$0.1425 from A$0.1467, reflecting updated assumptions for slower revenue growth, lower profit margins, a slightly higher discount rate, and a higher future P/E multiple in line with recent sector research updates. Analyst Commentary Recent sector research on listed healthcare and medtech names provides some useful context for how the market is thinking about smaller health technology platforms like Alcidion Group, particularly around growth durability, product execution, and valuation support.Narrative Update • Feb 24
ALC: Improved Execution And Sector Readthroughs Will Support Repriced Earnings Outlook
Analysts made only a marginal adjustment to their Alcidion Group price target, keeping fair value around A$0.15 as small tweaks to the discount rate and future P/E assumptions were weighed against mixed sector readthroughs from recent peer research. Analyst Commentary Recent sector research on peers in medical technology and ophthalmology has given analysts a mixed backdrop to frame Alcidion Group, with sentiment splitting between those who see room for upside if execution improves and those who are more cautious on growth assumptions and risk.Narrative Update • Feb 10
ALC: Clearer Medium Term Execution Will Support Repriced Earnings Outlook
Analysts have modestly adjusted their price target for Alcidion Group to reflect a slightly higher discount rate and P/E assumption, bringing their view more closely in line with recent peer research and updated risk assessments. Analyst Commentary Recent Street research on adjacent healthcare names highlights how investors are thinking about valuation, growth visibility, and execution risk, which is relevant context as you weigh Alcidion Group.Narrative Update • Jan 26
ALC: Clearer Multi Year Pipeline Visibility Will Support Repriced Earnings Outlook
Narrative Update on Alcidion Group Analysts have lifted their Alcidion Group price target by about A$0.01 to A$0.15, reflecting updated assumptions for revenue growth, profit margins and a lower future P/E multiple. Analyst Commentary Recent Street research on healthcare and medtech names highlights how quickly sentiment can shift as new information comes through on growth visibility, installation pipelines and deal outcomes.Analysis Article • Jan 14
Alcidion Group Limited (ASX:ALC) Surges 33% Yet Its Low P/S Is No Reason For Excitement
Alcidion Group Limited ( ASX:ALC ) shares have continued their recent momentum with a 33% gain in the last month alone...Narrative Update • Jan 10
ALC: Higher Revenue Visibility Will Support Repriced Earnings Multiple Outlook
Analysts have lifted their fair value estimate for Alcidion Group from A$0.12 to about A$0.14, reflecting updated assumptions for revenue growth, profit margins and future P/E that are broadly consistent with recent, mixed but engaged Street views on comparable health tech names. Analyst Commentary Recent Street research on global health tech and medical device names provides a sense of how investors are thinking about execution risk, capital allocation and valuation, even though it does not relate directly to Alcidion Group.Analysis Article • Nov 12
Alcidion Group Limited (ASX:ALC) Looks Inexpensive But Perhaps Not Attractive Enough
With a price-to-sales (or "P/S") ratio of 3.5x Alcidion Group Limited ( ASX:ALC ) may be sending very bullish signals...Analysis Article • Jun 24
There's No Escaping Alcidion Group Limited's (ASX:ALC) Muted Revenues Despite A 30% Share Price Rise
The Alcidion Group Limited ( ASX:ALC ) share price has done very well over the last month, posting an excellent gain of...
New Narrative • May 03
North Cumbria And Wales Expansion Will Broaden Health Tech Horizons
Successful contract signings and renewals in new regions indicate potential for substantial revenue growth and enhanced financial stability.Analysis Article • Apr 24
Calculating The Intrinsic Value Of Alcidion Group Limited (ASX:ALC)
Key Insights The projected fair value for Alcidion Group is AU$0.071 based on 2 Stage Free Cash Flow to Equity With...Analysis Article • Feb 11
Alcidion Group Limited's (ASX:ALC) Shares Bounce 29% But Its Business Still Trails The Industry
Despite an already strong run, Alcidion Group Limited ( ASX:ALC ) shares have been powering on, with a gain of 29% in...Analysis Article • Aug 16
Alcidion Group Limited (ASX:ALC) Held Back By Insufficient Growth Even After Shares Climb 41%
Alcidion Group Limited ( ASX:ALC ) shareholders have had their patience rewarded with a 41% share price jump in the...Analysis Article • Jul 24
Here's Why We're Not Too Worried About Alcidion Group's (ASX:ALC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysis Article • Jun 14
Benign Growth For Alcidion Group Limited (ASX:ALC) Underpins Stock's 28% Plummet
Alcidion Group Limited ( ASX:ALC ) shares have had a horrible month, losing 28% after a relatively good period...Analysis Article • Apr 24
We're Hopeful That Alcidion Group (ASX:ALC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysis Article • Jan 30
Little Excitement Around Alcidion Group Limited's (ASX:ALC) Revenues As Shares Take 29% Pounding
Alcidion Group Limited ( ASX:ALC ) shareholders that were waiting for something to happen have been dealt a blow with a...Analysis Article • Nov 13
Shareholders Will Probably Hold Off On Increasing Alcidion Group Limited's (ASX:ALC) CEO Compensation For The Time Being
Key Insights Alcidion Group's Annual General Meeting to take place on 20th of November Total pay for CEO Kate Quirke...Analysis Article • Oct 19
Companies Like Alcidion Group (ASX:ALC) Can Afford To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Jul 17
We're Interested To See How Alcidion Group (ASX:ALC) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Jun 02
Is There An Opportunity With Alcidion Group Limited's (ASX:ALC) 45% Undervaluation?
Key Insights Using the Dividend Discount Model, Alcidion Group fair value estimate is AU$0.17 Alcidion Group is...Analysis Article • Feb 25
Alcidion Group Limited (ASX:ALC) Just Reported And Analysts Have Been Cutting Their Estimates
Last week saw the newest half-yearly earnings release from Alcidion Group Limited ( ASX:ALC ), an important milestone...Shareholder Returns
| ALC | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 2.3% | 21.9% | -1.2% |
| 1Y | 17.0% | -36.2% | 0.8% |
Return vs Industry: ALC exceeded the Australian Healthcare Services industry which returned -36.2% over the past year.
Return vs Market: ALC exceeded the Australian Market which returned 0.8% over the past year.
Price Volatility
| ALC volatility | |
|---|---|
| ALC Average Weekly Movement | 7.2% |
| Healthcare Services Industry Average Movement | 9.7% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in AU Market | 17.1% |
| 10% least volatile stocks in AU Market | 4.1% |
Stable Share Price: ALC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ALC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 136 | Kate Quirke | www.alcidion.com |
Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. It offers Miya Precision, a fast healthcare interoperability resource (FHIR)-events platform that integrates digital patient care services, such as a clinical decision support system, electronic patient record (EPR), and patient administration systems (PAS). The company platform also provides electronic patient flow journey boards; virtual care and remote patient management; integrated care system smart operations center; emergency department and specialized care; real-time data integration, FHIR-based interoperability, and predictive analytics; modern modular EPR; and streamlined clinical workflows, intelligent comms, and mobility solutions.
Alcidion Group Limited Fundamentals Summary
| ALC fundamental statistics | |
|---|---|
| Market cap | AU$147.72m |
| Earnings (TTM) | AU$3.87m |
| Revenue (TTM) | AU$48.62m |
38.1x
P/E Ratio3.0x
P/S RatioIs ALC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALC income statement (TTM) | |
|---|---|
| Revenue | AU$48.62m |
| Cost of Revenue | AU$6.98m |
| Gross Profit | AU$41.64m |
| Other Expenses | AU$37.77m |
| Earnings | AU$3.87m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0029 |
| Gross Margin | 85.65% |
| Net Profit Margin | 7.97% |
| Debt/Equity Ratio | 0% |
How did ALC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/06 20:07 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alcidion Group Limited is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elyse Shapiro | Bell Potter |
| Thomas Wakim | Bell Potter |
| Aksel Salins | Canaccord Genuity |